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                      Choledocholithiasis is defined as the occurrence of stones in 
the bile ducts. It is a common clinical problem worldwide. It has been 
estimated that 10–15% of patients undergoing cholecystectomy for 
symptomatic gallstones harbor concomitant stones in their CBD. Primary 
ductal stones formed de novo also add a further small percentage to the 
overall prevalence. 
                       Like stones in the gallbladder, stones in the bile ducts may 
remain asymptomatic for years, and stones from the bile duct are known to 
pass silently into the duodenum, perhaps frequently. 
                      Unlike stones in the gallbladder, which usually become 
clinically evident as relatively benign episodes of recurrent biliary pain, 
stones in the CBD, when they do cause symptoms, tend to present as life-
threatening complications such as cholangitis and acute pancreatitis. 
Therefore, discovery of choledocholithiasis generally should be followed by 
some type of intervention to remove the stones. 
                       
 
                      Studies regarding choledocholithiasis in South India are very 
limited. Hence I have chosen to analyse various clinical presentations of 
choledocholithiasis, success rate and complications of endotherapy in those 
patients. 


























 REVIEW OF LITERATURE 
                     CBD stones are either primary or secondary. Primary stones 
arise within the biliary duct system, while secondary stones develop in the 
gallbladder and migrate to the CBD. In the United States, up to 85% of all 
CBD stones are secondary in origin. 
                   Primary CBD stones are caused by conditions leading to bile  
stasis and chronic bactibilia. Up to 90% of patients with brown pigment 
CBD stones have bile culture results positive for bacteria. Primary duct 
stones are usually brown pigment stones. Brown stones differ from black 
pigment stones by having a higher content of cholesterol. Brown stones are 
soft and earthy in consistency and take the shape of the duct. 
    In Western populations, biliary stasis is secondary to factors 
such as sphincter of Oddi dysfunction, benign biliary strictures, sclerosing 
cholangitis, and cystic dilatation of the bile ducts. Bile stasis promotes 
growth of bacteria, which produce phospholipase A1, thus releasing fatty 
acids from biliary phospholipids. The duct epithelium and/or bacteria (eg, 
Escherichia coli) produce beta-glucuronidase in amounts sufficient to 
deconjugate bilirubin diglucuronide. The presence of free fatty acids, 
deconjugated bilirubin, and bile acids leads to the formation of insoluble 
 calcium bilirubinate particles. With the loss of bile acids, cholesterol 
becomes insoluble, resulting in the formation of biliary sludge. The sludge 
also contains mucin and bacterial cytoskeletons, which further aid in stone 
formation. 
                    In Asian populations, infestation with A lumbricoides and C 
sinensis may promote stasis by either blocking the biliary ducts or by 
damaging the duct walls, resulting in stricture formation. Bactibilia is also 
common in these instances, probably secondary to episodic portal 
bacteremia. Some authors have suggested that the stones are formed because 
of the bactibilia alone and that the parasites presence is just a coincidence. 
               Secondary CBD stones arise from the gallbladder, migrate to 
the CBD, and have a typical spectrum of cholesterol stones and black 
pigment stones. 
               Bacteria can be cultured from the surface of cholesterol and 
pigment stones but not from the core, suggesting that bacteria do not play a 
role in their formation. 
 
           
  
  The prerequisites for the formation of cholesterol stones are      
                       1.cholesterol supersaturation 
                       2.stasis and  
                      3.accelerated nucleation. 
                    The sex of the patient, parity, obesity, weight loss, and genetics 
are risk factors for the development of cholesterol stones. 
     Black pigment stones typically occur in conditions in which 
bilirubin excretion is increased, as in hemolytic disorders and in situations 
associated with profound gallbladder stasis such as prolonged fasting and 
long-term parenteral nutrition. Pigment stones are more common in patients 
with cirrhosis and ileal disease, although the exact mechanism of stone 
formation under these conditions is not understood. 
                    Gallstones may pass from the gallbladder into the CBD or can 
form de novo in the duct. Generally, all gallstones from one patient, whether 
from the gallbladder or CBD, are of one type, either cholesterol or pigment. 
                    Cholesterol stones form only in the gallbladder, and any 
cholesterol stones found in the CBD must have migrated there from the 
 gallbladder. Black pigment stones, which are associated with old age, 
hemolysis, alcoholism, and cirrhosis, also form in the gallbladder and only 
rarely migrate into the CBD.  
                     The majority of pigment stones in the CBD are the softer 
brown pigment stones. These stones form de novo in the CBD as a result of 
bacterial action on phospholipid and bilirubin in bile.[1] They are often found 
proximal to biliary strictures and are frequently associated with cholangitis. 
Brown pigment stones are found in patients with recurrent pyogenic 
cholangitis.[2]  
                    Fifteen percent of patients with gallbladder stones also have 
CBD stones. Conversely, of patients with ductal stones, 95% also have 
gallbladder stones.[3]  
                    In patients who present with choledocholithiasis months or 
years after a cholecystectomy, determining whether the stones were 
overlooked at the earlier operation or have formed since then may be 
impossible. Obviously, if the chemical composition of the CBD stones is 
determined, cholesterol or black pigment stones can be presumed to have 
been left behind after the original operation, whereas brown pigment stones 
can be presumed to have formed de novo since the cholecystectomy.[1]  
                     In fact, formation of pigment stones in the CBD is also a late 
complication of endoscopic sphincterotomy.[4] In a study of the long-term 
consequences of endoscopic sphincterotomy in more than 400 patients, the 
cumulative frequency of recurrent CBD stones was 12%; all the recurrent 
stones were of the brown pigment type, irrespective of the chemical 
composition of the original gallstones. This observation suggests that 
sphincterotomy permits chronic bacterial colonization of the CBD that 
results in deconjugation of bilirubin and precipitation of pigment stones. 
                    Stones in the CBD usually come to rest at the lower end of the 
ampulla of Vater. Obstruction of the bile duct raises bile pressure proximally 
and causes the ducts to dilate. Pressure in the CBD is normally 10 to 15 cm 
H2O and rises to 25 to 40 cm H2O with complete obstruction. When pressure 
exceeds 15 cm H2O, bile flow decreases, and at 30 cm H2O, bile flow stops. 
                    The bile duct dilates to the point that it can be detected on either 
ultrasonography or abdominal CT in approximately 75% of cases. In the 
patient who has had recurrent bouts of cholangitis, the bile duct may become 
fibrotic and thus unable to dilate. Moreover, dilatation of the duct is 
sometimes absent in patients with choledocholithiasis because the 
obstruction is low-grade and intermittent. 
 CLINICAL FEATURES  
                     Choledocolithiasis can present as following ways. 
1. Abdominal pain 
2. Obstructive jaundice 
3. Cholangitis 
4. Biliary pancreatitis and 
5. Asymptomatic. 
Pain 
                     Dull right upper abdominal pain due to increased biliary tree 
pressure may also be experienced as a result of stone impaction. 
Obstructive jaundice 
                     Intermittent jaundice is said to be a typical feature of 
choledocholithiasis, when the stone impacts and disimpacts at the papilla or 
the distal CBD leading to fluctuating jaundice and serum bilirubin levels. 
Continuous obstruction from stone impaction in the distal common duct may 
manifest as progressive jaundice. 
Clinical cholangitis 
                     When bacterial infection superimposes in the obstructed biliary 
system, the patient presents with the typical Charcot’s triad (fever, pain, and 
jaundice) of cholangitis. Nevertheless, cholangitis may not necessarily 
 present with all three features, and the diagnosis should not be dismissed 
lightly just because the patient is afebrile or not jaundiced. 
Biliary pancreatitis 
                     Small stones may pass spontaneously through the ampulla of 
Vater. The passage of stones across the papilla may induce a transient rise in 
the pancreatic duct pressure and trigger intrapancreatic activation of 
enzymes resulting in acute pancreatitis. Patients with acute pancreatitis 
typically present with epigastric pain radiating to the back, associated with 
nausea and vomiting. A serum amylase level exceeding 1000 IU/liter is 
considered to be diagnostic of pancreatitis. 
                     The morbidity of choledocholithiasis stems principally from 
biliary obstruction, which raises biliary pressure and diminishes bile flow. 
The rate of onset of obstruction, its extent, and the amount of bacterial 
contamination of the bile are the major factors that determine the re-sulting 
symptoms.  
                    Acute obstruction usually causes biliary pain and jaundice, 
whereas obstruction that develops gradually over several months may 
manifest initially as pruritus or jaundice alone.[5] If bacteria proliferate, life-
threatening cholangitis  may result. 
                     The physical findings are usually normal if obstruction of the 
CBD is intermittent. Mild to moderate jaundice may be noted when 
obstruction has been present for several days to a few weeks. Deep jaundice 
without pain, particularly with a palpable gallbladder (Courvoisier's sign), 
suggests neoplastic obstruction of the CBD, even when the patient has 
stones in the gallbladder. With long-standing obstruction, secondary biliary 
cirrhosis may result, leading to physical findings of chronic liver disease. 
                    Sometimes, results of laboratory studies may be the only clue to 
the presence of choledocholithiasis.[6] With bile duct obstruction, serum 
bilirubin and alkaline phosphatase levels both increase. Bilirubin 
accumulates in serum because of blocked excretion, whereas alkaline 
phosphatase levels rise because of increased synthesis of the enzyme by the 
canalicular epithelium. The rise in the alkaline phosphatase level is more 
rapid than and precedes the rise in bilirubin level.[7]  
                    The absolute height of the serum bilirubin level is proportional 
to the extent of obstruction, but the height of the alkaline phosphatase level 
bears no relationship to either the extent of obstruction or its cause. In cases 
of choledocholithiasis, the serum bilirubin level is typically in the range of 2 
to 5 mg/dL[5] and rarely exceeds 12 mg/dL.  
                     Transient “spikes” in serum aminotransferase or amylase levels 
suggest passage of a common duct stone into the duodenum. The overall 
sensitivity of liver biochemical testing for detecting choledocholithiasis is 
reported to be 94%; serum levels of gamma glutamyl transpeptidase are 
elevated most commonly but may not be assessed in clinical practice.[7]  
NATURAL HISTORY  
                     Little information is available on the natural history of 
asymptomatic CBD stones. In many patients such stones remain 
asymptomatic for months or years, but available evidence suggests that the 
natural history of asymptomatic CBD stones is less benign than that of 
asymptomatic gallstones. [5] [8]  
DIAGNOSIS  
                    Ultrasonography actually visualizes CBD stones in only about 
50% of cases, [60] whereas dilatation of the CBD to a diameter greater than 6 
mm is seen in about 75% of cases. Ultrasonography can confirm or at least 
suggest the presence of CBD but cannot exclude choledocholithiasis 
definitively. 
                     EUS, although clearly more invasive than standard 
ultrasonography, has the advantage of visualizing the CBD more accurately. 
In preliminary studies, EUS has excluded or confirmed choledocholithiasis 
with sensitivity and specificity rates of approximately 98% as compared 
with ERCP. [62]  
                    ERCP is the standard method for the diagnosis and therapy of 
CBD stones, [9] with sensitivity and specificity rates of approximately 95%. 
However, less invasive studies, such as EUS and MRCP, should be 
performed first when the clinical probability of choledocholithiasis is low.[63]  
                     Percutaneous transhepatic cholangiography (percutaneous 
THC) is also an accurate test for confirming the presence of 
choledocholithiasis. The procedure is most readily accomplished when the 
intrahepatic bile ducts are dilated and now is performed primarily when 
ERCP is unavailable or has been technically unsuccessful.  
                     Laparoscopic ultrasonography is a new imaging modality 
employed in the surgical suite immediately before mobilization of the 
gallbladder during cholecystectomy. Preliminary studies suggest that 
laparoscopic ultrasonography may be as accurate as surgical 
 cholangiography in detecting CBD stones and may thereby obviate the need 
for the latter. [10]  
DIFFERENTIAL DIAGNOSIS  
                     Symptoms caused by obstruction of the CBD cannot be 
distinguished from those caused by obstruction of the cystic duct. Therefore, 
biliary pain is always in the differential diagnosis in patients with an intact 
gallbladder. The presence of jaundice or abnormal liver biochemical results 
strongly points to the bile duct rather than the gallbladder as the source of 
the pain. 
                     In patients who present with jaundice, malignant obstruction of 
the bile duct or obstruction from a choledochal cyst may be indistinguishable 
clinically from choledocholithiasis . 
                      Acute passive congestion of the liver, associated with cardiac 
decompensation, may cause intense RUQ pain, tenderness, and even 
jaundice with serum bilirubin levels higher than 10 mg/dL ; however, fever 
is usually absent, and the WBC count is normal or only slightly elevated. 
The patient typically has other obvious signs of cardiac decompensation. 
 Constrictive pericarditis and cor pulmonale also may cause acute congestion 
of the liver with only subtle cardiac findings. 
                    Acute viral hepatitis rarely may cause severe RUQ pain with 
tenderness and fever. The WBC count, however, usually is not elevated, 
whereas serum alanine aminotransferase and aspartate aminotransferase 
levels are markedly elevated. 
                    Acquired immunodeficiency syndrome (AIDS)–associated 
cholangiopathy[11] and papillary stenosis must be considered in human 
immunodeficiency virus–positive patients with RUQ pain and abnormal 
liver biochemical test results. 
TREATMENT  
                    Given its propensity to result in serious complications such as 
cholangitis and acute pancreatitis, choledocholithiasis warrants treatment in 
nearly all cases.[12] The optimal therapy for a given patient depends on the 
severity of symptoms, presence of coexisting medical problems, availability 
of local expertise, and presence or absence of the gallbladder. 
                    CBD stones discovered at the time of a laparoscopic 
cholecystectomy present a dilemma to the surgeon. The operation can be 
 converted to an open cholecystectomy with CBD exploration, but this 
approach results in greater morbidity and a more prolonged hospital stay. 
                   Alternatively, the laparoscopic cholecystectomy can be carried 
out as planned, and the patient can return for ERCP with removal of the 
CBD stones. Such an approach, if successful, cures the disease but runs the 
risk of necessitating a third procedure, namely a CBD exploration, if the 
stones cannot be removed at ERCP. In general, the greater the expertise of 
the therapeutic endoscopist, the more inclined the surgeon should be to 
complete the laparoscopic cholecystectomy and have the CBD stones 
removed endoscopically.[12]  
                    In especially high-risk patients, endoscopic removal of CBD 
stones may be performed without cholecystectomy. This approach is 
particularly appropriate for elderly patients with other severe illnesses.[13] 
Studies indicate that cholecystectomy is required subsequently for recurrent 
symptoms in only 10% of patients. 
TREATMENT OF CHOLEDOCHOLITHIASIS  
                    Choledocholithiasis may be detected at the same time that 
gallbladder stones are discovered during an evaluation for biliary tract 
 symptoms, during a cholecystectomy, or after a cholecystectomy. Several 
management options are available, including dissolution therapy, 
interventional radiologic and endoscopic techniques, and surgery. Which 
management strategy is most appropriate for a given patient depends on the 
clinical presentation (jaundice, cholangitis, pancreatitis, or absence of 
symptoms), status of the gallbladder, and age and general condition of the 
patient. Additional factors to consider are the expertise of the available 
endoscopic, radiologic, and surgical specialists. 
CHOLEDOCHOLITHIASIS KNOWN PREOPERATIVELY  
                     When choledocholithiasis is known to exist before 
cholecystectomy, an acceptable option is to clear the common bile duct with 
endoscopic papillotomy and then proceed with laparoscopic 
cholecystectomy. [16,17] Alternative approaches include open or laparoscopic 
cholecystectomy with a common bile duct exploration.  
                     The results of small, randomized trials suggest that there are no 
important differences in the efficacy and safety of precholecystectomy 
endoscopic sphincterotomy and open common bile duct exploration. [18] [19] 
Another study has shown the efficacy and safety of precholecystectomy 
endoscopic sphincterotomy and laparoscopic cholecystectomy with a 
 laparoscopic bile duct exploration to be equivalent.[20] The laparoscopic 
approach resulted in fewer procedures and a shorter overall hospital stay. 
CHOLEDOCHOLITHIASIS  IDENTIFIED  DURING  
CHOLECYSTECTOMY 
                     If unsuspected choledocholithiasis is identified on 
cholangiography during laparoscopic cholecystectomy, the following three 
options are available: (1) conversion to an open operation with a common 
bile duct exploration; (2) laparoscopic common bile duct exploration (via 
choledoscopy); and (3) completion of the laparoscopic cholecystectomy 
followed by postoperative endoscopic sphincterotomy and stone extraction. 
                     Factors that influence the choice of treatment include the 
number and location of common duct stones, the presence of associated 
ductal disease, and the skill and experience of the surgeon and endoscopist. 
Completion of the laparoscopic cholecystectomy followed by postoperative 
endoscopic sphincterotomy is satisfactory for most patients and has the 
advantage of preserving the minimally invasive approach.  
                     However, endoscopic sphincterotomy may be technically 
unsuccessful in 5% to 10% of patients, even in the hands of a skilled 
 endoscopist, and complete bile duct clearance of stones is possible in only 
70% to 80% of patients.[21] In the patients in whom an initial endoscopic 
sphincterotomy is unsuccessful, a second attempt may be required. 
                    Growing experience has shown that laparoscopic common bile 
duct exploration is safe and effective. Stone clearance rates average 95%, 
with an operative mortality rate of 0.5%. [20] [22] [23]  
                     Laparoscopic common bile duct exploration compares 
favorably with endoscopic sphincterotomy in terms of efficacy, cost, and 
safety. [24] [25] Stones are removed via the cystic duct.  
                     On the rare occasions that bile duct stones are too large or are 
located above the insertion of the cystic duct, a transcholedochal approach is 
needed, followed by bile duct closure over a T-tube left in the bile duct with 
the “T” brought out through the skin, to prevent stricturing of the bile duct.  
                       A T-tube may also be left in the bile duct when stone 




 CHOLEDOCHOLITHIASIS  IDENTIFIED  AFTER 
CHOLECYSTECTOMY  
                     Choledocholithiasis identified in patients who have previously 
undergone cholecystectomy is best managed with endoscopic 
sphincterotomy and stone extraction. If a T-tube is still present from a recent 
common bile duct exploration, radiologic extraction of the stone via the T-
tube tract is usually possible. Surgery rarely is required in this situation. 
ENDOSCOPIC INTERVENTION  
                     ERCP was first described by McCune and coworkers in 
1968.[26] Technologic advances in video endoscopy have improved image 
resolution, facilitated the teaching of advanced procedures, and permitted the 
digitization of radiographic and endoscopic images. Patients who undergo 
endoscopic intervention usually receive sedation and analgesia (conscious 
sedation), and only rarely general anesthesia. 
                    The side-viewing endoscope has a viewing field that is 
perpendicular to the long axis of the instrument to permit better visualization 
of the medial wall of the descending duodenum, the usual location of the 
duodenal papilla. Selective cannulation of the biliary tree and diagnostic 
 ERCP is the first step in a therapeutic procedure. Various diagnostic and 
therapeutic duodenoscopes with channels of different sizes are available. 
“Mother-daughter” scopes (cholangioscopes that can be inserted through a 
4.2-mm channel of a standard duodenoscope) are available.  
                     Forward-viewing instruments may be better for locating the 
papilla in a patient with a Billroth II gastrojejunostomy, although a side-
viewing duodenoscope is still preferred because of its elevator. The most 
versatile approach is to use a duodenoscope with a small insertion tube and 
4.2-mm channel for all interventions. Reusable accessories help keep costs 
down but require reliable sterilization.[27]  
                     Complications associated with diagnostic and therapeutic 
cholangiography include infection, bleeding, pancreatitis,[28] retroduodenal 
perforation,[29] and impaction of a stone or retrieval basket. Complications of 
varying severity occur in 5% to 10% of endoscopic biliary interventions, and 
increased experience by the endoscopist results in fewer complications.[30]  
                    Duodenal perforation and pancreatitis are more common in 
patients with papillary stenosis than in those with other biliary disorders, and 
the risk of bleeding is greater in patients with papillary tumors. Prophylactic 
use of somatostatin or gabexate mesylate may reduce the risk of pancreatitis; 
 however, these agents are not used routinely because of controversy related 
to their efficacy, patient selection, ease of administration, and cost. [31] [32] [33]                                   
                    The risk of post-ERCP pancreatitis is higher in women, in 
patients with sphincter of Oddi dysfunction, in those with previous ERCP-
associated pancreatitis, in patients in whom the pancreatic duct is filled 
excessively with contrast dye, and in those in whom a precut papillotomy is 
performed.[34]  
                    In general, the risk of complications is not higher in patients 
with a duodenal diverticulum, although the vascular supply to the papilla is 
distorted.[29] Patients in whom an obstructed cystic duct is seen at ERCP are 
probably at increased risk of acute cholecystitis after endoscopic 
sphincterotomy for CBD stones.[30] Late complications of ERCP include 
acute cholecystitis, stenosis of the papilla, cholangitis, and retained or new 
CDB stones. 
                    Previous surgery, such as a Billroth II gastrojejunostomy or 
Roux-en-Y choledochojejunostomy, makes ERCP difficult or impossible. A 
major complication in a patient with a Billroth II anatomy is bowel 
perforation of the afferent limb, which may require surgical intervention.[35] 
Uncorrectable coagulopathy also is associated with increased risk and may 
 represent a contraindication to ERCP and especially endoscopic 
sphincterotomy.  
                    As noted earlier, inexperience of the biliary endoscopist (<200 
cases per year) and use of a precut papillotomy to gain access to the bile duct 
are independent risk factors for major complications.[36]  
                    The routine use of antibiotics prior to ERCP is controversial, but 
oral antibiotic prophylaxis appears to be safe and cost-effective in patients 
undergoing therapeutic ERCP. [37] [38] Adequate sedation is of the utmost 
importance, and if standard sedation and analgesia are not possible or are too 
dangerous, general anesthesia must be considered. Midazolam (a 
benzodiazepine) and meperidine (a narcotic) are generally administered. 
                    In the past, droperidol was often used with midazolam and 
meperidine to facilitate sedation in patients who were otherwise difficult to 
sedate. Because droperidol prolongs the QT interval, however, and can lead 
to cardiac arrest when used in combination with certain drugs, the FDA has 
issued a warning about the use of droperidol, along with the requirement for 
a pre-procedure electrocardiogram (ECG) and 2 hours of continuous ECG 
monitoring after the procedure. This requirement has eliminated the use of 
 droperidol during ERCP. Diphenhydramine and pro-methazine are now used 
in its place. 
                     Nowadays, propofol is used to achieve sedation in patients 
undergoing ERCP. This agent can quickly cause respiratory depression and 
should be administered only by persons with appropriate training. Silent 
myo-cardial ischemia has been reported to occur much more frequently than 
previously appreciated during ERCP, although the clinical implication of 
silent ischemia is not clear.[39]  
                    The duodenal papilla usually is identified without difficulty.[40] 
In patients with a normal anatomy, cannulation of the papilla is usually 
successful, but to achieve better than a 95% success rate, a precut 
papillotomy may be needed.[41] Neither cholangitis nor pancreatitis is a 
contraindication to ERCP if a thera-peutic maneuver is being considered. 
Competence in therapeutic ERCP requires specialized training and 
mentoring.[42] When an attempt at ERCP fails, the patient may need to be 
referred to a specialized center with a more experienced endoscopist trained 
in advanced techniques.  
                     Success rates higher than 96% with an acceptable complication 
rate of 10% should be expected. [43] [44] [45] [46] New cannulation techniques are 
 always being developed.[47] Storage of data and images is particularly 
important with therapeutic procedures; the precise anatomy must be 
delineated for surgical and radiologic colleagues.  
                      Patients can often be discharged home after a therapeutic 
ERCP, but those who experience pain after the procedure, have had 
pancreatitis in the past, have suspected sphincter of Oddi dysfunction, have 
cirrhosis, or have had a difficult cannulation or a precut papillotomy are at 
higher risk of a complication and should be admitted to the hospital for 
observation. [48] [49] [50] [51] [52]  
ENDOSCOPIC SPHINCTEROTOMY  
                     Endoscopic sphincterotomy is the preferred therapy for retained 
CBD stones and is successful in more than 90% of cases.[53]  
TECHNIQUE  
                     The sphincter muscle is cut at the ampulla with a unipolar 
blended current applied through a sphincterotome (i.e., a 
polytetrafluroethylene catheter with a threaded piece of conducting wire at 
its end). Sphincterotomes are available with different configurations—pull, 
push, and needle-knife. 
                     The landmark that helps determine the safe extent of the cut is 
the intraduodenal portion of the CBD. As a general rule, the incision of the 
sphincterotomy is stopped when it reaches the transverse fold located 
superior to the papilla. The blood supply to this area can be variable, 
especially in the presence of a diverticulum. The cut is performed with short 
bursts of current, so that the disruption is accomplished with minimal 
transmural burn, good coagulation, and minimal “unzipping.” Most 
sphincterotomes accept a guidewire for greater security.  
                     The size of the sphincterotomy is determined by the therapeutic 
objectives (i.e., when a large stone is to be removed, the required cut is 
larger than when the papillary opening must be enlarged slightly to permit 
placement of an endoprosthesis).  
                       Occasionally, a precut sphincterotomy is performed to assist 
passage of the diagnostic catheter, and on some occasions, a needle-knife is 
employed in place of a sphincterotome to gain access to a bile duct that is 
totally obstructed or that cannot be cannulated. Rarely, a 
choledochoduodenal fistula may be created in the supra-ampullary area 
when the ampulla is totally occluded by a tumor or stone. 
 
 STONE REMOVAL  
                    Except under exceptional circumstances (i.e., aberrant anatomy 
or uncorrectable coagulopathy) an endoscopic sphincterotomy is performed 
prior to removal of a stone in the bile duct. Stones in the CBD may pass 
spontaneously with the initial gush of bile that follows endoscopic 
sphincterotomy, or they may be retrieved easily with an occlusion balloon or 
wire basket.  
                     When the bile duct cannot be entered, a needle-knife is used to 
cut into the duct. The safety of this technique is operator dependent; 
bleeding, perforation, and incomplete cuts occur more commonly in 
inexperienced than in experienced hands. With a dilated bile duct and a 
longer intraduodenal ductal segment, the risk of complications associated 
with use of a needle-knife is less. 
                     Balloon dilation of the papilla prior to removal of small stones 
has achieved some popularity because of uncertainty about the long-term 
effects of endoscopic sphincterotomy and the desire to eliminate the risks 
associated with it. The stone is extracted after the papilla is dilated, and the 
competence of the papilla is preserved. Some investigators continue to have 
 concerns about pancreatitis associated with dilation of the papilla. Clearly, 
balloon dilation is not suitable for removal of large stones (>1 cm).[54]  
                    Long-term use of an endoprosthesis for stone disease is 
questionable, particularly when the projected survival of the patient exceeds 
a year. There is a risk of sepsis despite the oral administration of 
ursodeoxycholic acid to prolong the patency of a plastic stent. The use of 
metal stents for stone disease is untested; such stents typically become 
occluded within a year and cannot be removed. [55] [56]  
                    Large CBD stones (>1.5 cm) may require a more sophisticated 
technique for removal, such as (1) mechanical lithotripsy, (2) piezo-
mechanical lithotripsy, (3) laser lithotripsy,[57] or (4) ESWL after placement 
of a naso-biliary catheter to target the stone correctly. If a stone is left 
behind, placement of a short stent in the bile duct or a nasobiliary catheter is 
often advisable to prevent impaction of the stone until definitive therapy is 
undertaken.  
                    Large CBD stones that cannot be removed from a patient with a 
low surgical risk represent an indication for surgery. In general, when 
choledocholithiasis and cholelithiasis coexist, the CBD stones are removed 
via ERCP, and laparoscopic cholecystectomy is then performed. 
                      If an elective open cholecystectomy is planned, preoperative 
ERCP may have greater morbidity than a CBD at the time of 
cholecystectomy. In patients who do not undergo a cholecystectomy after 
endoscopic sphincterotomy to remove CBD stones, the risk of acute 
cholecystitis is approximately 5.9% after a mean of 7.7 years of follow-
up.[58] ERCP in patients with gallstone pancreatitis is generally reserved for 
patients who are severely ill and those with jaundice, cholangitis, or 
nonresolving pancreatitis.[59]  
CHOLANGITIS 
                    Of all the complications of gallstones, cholangitis kills most 
swiftly. Pus under pressure in the bile ducts leads to rapid spread of bacteria 
via the liver into the blood, with resulting septicemia. Moreover, the 
diagnosis of cholangitis is often problematic (especially in the critical early 
phase of the disease), because clinical features pointing to the biliary tract as 
the source of sepsis are often absent.[80]  
                    Careful evaluvation of the symptoms, signs, and laboratory 
findings that can aid in an early diagnosis of cholangitis. 
 
 Etiology and Pathophysiology  
                      In approximately 85% of cases, cholangitis is caused by an 
impacted stone in the CBD, with resulting bile stasis.[81] Other causes of bile 
duct obstruction that may result in cholangitis are neoplasms, biliary 
stricture, parasitic infections, and congenital abnormalities of the bile ducts. 
This discussion deals specifically with cholangitis caused by gallstones in 
the CBD. 
                      Bile duct obstruction is necessary, but not sufficient, to cause 
cholangitis. Cholangitis is relatively common in patients with 
choledocholithiasis and nearly universal in patients with post-traumatic bile 
duct stricture but is seen in only 15% of patients with neoplastic obstruction 
of the CBD. It is most likely to result when a bile duct that already contains 
bacteria becomes obstructed, as is the case in most patients with 
choledocholithiasis and stricture but in few patients with neoplastic 
obstruction.  
                    Malignant obstruction is more often complete than obstruction 
by a stricture or a CBD stone and less commonly permits the reflux of 
bacteria from duodenal contents into the bile ducts.[82]  
 Clinical Features  
                     The hallmark of cholangitis is Charcot's classic triad, consisting 
of RUQ pain, jaundice, and fever. The full triad is present in only 70% of 
patients.[82] Altered mental status and hypotension in combination with 
Charcot's triad, known commonly as Reynolds's pentad, occur in severe 
suppurative cholangitis. 
                    On physical examination, fever is almost universal, occurring in 
95% of patients. RUQ tenderness is elicited in approximately 90% of 
patients, but jaundice is clinically detectable in only 80%. Notably, 
peritoneal signs are found in only 15% of patients. The combination of 
hypotension and mental confusion indicates gram-negative septicemia. In 
overlooked cases of severe cholangitis, intrahepatic abscess may manifest as 
a late complication. 
Diagnosis  
                     The principles of radiologic diagnosis of cholangitis are the 
same as those for choledocholithiasis. Stones in the CBD are seen 
ultrasonographically in only about 50% of cases but can be inferred by 
detection of a dilated CBD in about 75% of cases.  
                     Normal ultrasonography findings do not exclude the possibility 
of choledocholithiasis in a patient in whom the clinical presentation suggests 
cholangitis.  
                     EUS and MRC, have a much higher accuracy rate than CT for 
detecting and excluding stones in the CBD. 
                     ERCP is the standard test for the diagnosis of CBD stones and 
cholangitis. Moreover, the ability of ERCP to establish drainage of infected 
bile under pressure can be life-saving. If ERCP is unsuccessful, 
percutaneous THC can be performed. 
Treatment  
                     In suspected cases of bacterial cholangitis, blood culture 
specimens should be obtained immediately and therapy started with 
antibiotics effective against the likely causative organisms.[83]  
                     In mild cases, initial therapy with a single drug, such as 
cefoxitin, 2.0 g intravenously every 6 to 8 hours, is usually sufficient. In 
severe cases, more intensive therapy (e.g., gentamicin, ampicillin, and 
metronidazole) is indicated. 
 
 GALLSTONE PANCREATITIS  
                     Initial management of patients with gallstone pancreatitis 
involves fluid resuscitation, bowel rest, and monitoring for complications. 
The majority of patients have a relatively mild illness that resolves clinically 
within 1 week with conservative management. 
                     The presence of cholelithiasis should be determined with 
ultrasonography early in the course of treatment of a patient with acute 
pancreatitis. For most patients with cholelithiasis, laparoscopic 
cholecystectomy should be performed before discharge. In the past, 
cholecystectomy early in the course of gallstone pancreatitis carried 
significant risk; for that reason, cholecystectomy was delayed for 1 to 2 
months to allow resolution of pancreatic inflammation.  
                     A major disadvantage of this delayed approach was that up to 
one half of patients had further attacks of pancreatitis while awaiting 
surgery. It is now recognized that cholecystectomy may be performed safely 
during the same hospitalization once the clinical signs of pancreatitis have 
resolved. [71] [72] [73] This approach shortens the total duration of both illness 
and hospitalization. Additionally, it prevents subsequent recurrent 
pancreatitis. Cholangiography should be performed during the 
 cholecystectomy to exclude residual common bile duct stones, as 
recommended by the International Association of Pancreatology.[74]  
                     In patients with severe or necrotizing pancreatitis, surgery is 
delayed for several weeks to allow  
                      (1) the patients to recover from the sequelae of pancreatitis;  
                       (2) inflammation of the hepatoduodenal ligament to subside, 
thereby permitting safe allowing surgical dissection; and  
                      (3) identification of patients in whom pancreatic pseudocysts 
develop and who thus may require additional surgical treatment.[75]  
                       A small subset of patients with necrotizing gallstone 
pancreatitis, particularly those with jaundice or cholangitis, appear to benefit 
from early endoscopic sphincterotomy and clearance of the common bile 
duct. [76] [77] 
                            
  Common bile duct stones are found in a substantial fraction of 
such patients when sphincterotomy is performed within the first 24 to 48 
hours of hospitalization. The morbidity of this approach is less than that of 
early surgery with common bile duct exploration.  
                       Most patients in whom endoscopic sphincterotomy is 
performed for gallstone pancreatitis should undergo elective 
cholecystectomy once the pancreatitis has subsided. 
                     In elderly patients or patients in whom surgery poses a high 
risk, cholecystectomy may be deferred, but further symptoms of gallstone 
disease may be expected in up to 25% on long-term follow up.[78] The risk of 
symptomatic gallstone disease is higher in patients in whom cystic duct 
















     









 OBJECTIVES OF THE STUDY 
 
1. To study the various clinical presentations of choledocholithiasis. 
2. To study the success rate of endotherapy in choledocholithiasis. 
3. To study the complications of endotherapy in choledocholithiasis. 
4. To study the epidemiology of choledocholithiasis. 
























 MATERIALS AND METHODS 
                     This is a prospective study conducted in DDHD, Government 
peripheral Hospital, Anna Nagar, Chennai – 102 from April 2008 to 
December 2009. 
INCLUSION & EXCLUSION CRITERIA: 
1. All patients with CBD stones who underwent ERCP were included in 
this study. 
2.  Patients with CBD stones not willing for ERCP were excluded from 
this study. 
3.  Patients with CBD stones who were all not fit for ERCP excluded. 
4.  Patients with obstructive jaundice other than CBD stones were 
excluded. 
                      All patients were explained about the procedure and its 
complications. We got informed consent from all the patients. ERCP was 
performed by the Professor and the Associate Professor of our department. 
All patients received premedications Inj. pentazocine 30mg (1cc), 
Inj.promethazine 50mg (2cc), Inj. hyoscine butylbromide 20mg (1cc), and 
Inj.midazolam 2mg I.V.  
  
Positioning of the patient 
                    ERCP is usually performed with the patient lying prone. It is 
important, however, to note that gravity will favor filling of specific parts of 
the pancreaticobiliary system with the patient in different positions. Turning 
the patient during ERCP examination may sometimes be necessary to 
eliminate overlapping shadows from superimposed bowel gas, bony 
structures, or the duodenoscope. This can also be achieved to some extent by 
rotation of a C-arm. Head up or down tilting of the X-ray table helps gravity 
drainage to fill the intrahepatic system or the distal common duct. 
                   At the end of the procedure, additional radiographs may be taken 
with the patient in a supine position. A change of position allows gravity to 
fill the more dependent portion of the right intrahepatic system and also the 
tail of the pancreas. 
                     Positioning the patient in the right oblique position moves CBD 
off the spine and may reveal the cystic duct which sometimes overlaps with 
the CBD. This position may also allow a better examination of the 
gallbladder. 
                     In rare circumstances, ERCP may be performed with the patient 
in a supine position. The endoscopist will have to adjust the position by 
rotating more to the right, or even work facing away from the X-ray table. 
 Cannulation with sphincterotome  
                    Cannulation of the common duct is usually done with ERCP 
cannula. Some patients may have stones impacted at the lower end of the 
common duct and the resultant bulging papilla could render cannulation 
more difficult. A cannulating sphincterotome with an adjustable tip may 
facilitate cannulation of the bile duct in this situation by lifting the roof of 
the papilla. The use of a hydrophilic guidewire under such circumstances 
may also help in selective cannulation.  
                    Deep cannulation of the bile duct should be confirmed by 
injecting a small amount of contrast through the sphincterotome or by gently 
wiggling the sphincterotome under fluoroscopy. 
 
Precut sphincterotomy for failed deep cannulation 
                     A needle-knife sphincterotome can be used to incise the lower 
end of the common duct when guidewire cannulation of the bile duct fails. 
In a recent prospective study by Binmoeller et al., precut papillotomy was 
performed on 123 out of 327 patients who had an unsuccessful CBD 
 cannulation [84]. Selective cannulation was achieved in all cases after the 
procedure, without a significant increase in the rate of pancreatitis and 
bleeding when compared to those undergoing the conventional pull-type 
endoscopic sphincterotomy. 
Complications of precut sphincterotomy 
                     Today, the overall incidence of complications following precut 
sphincterotomy has been reported to be 7–11%, which is not much higher 
than that quoted for conventional sphincterotomy [85,86]. However, it cannot 
be overemphasized that these figures were mostly produced by experienced 
endoscopists in worldrenowned centers. The mortality and morbidity rates 
could have been higher if the procedure had been performed by trainees or 
by the less experienced. 
Sphincterotomy  
                    A guidewire is inserted through the lumen of the cannulotome 
once deep cannulation is confirmed, so that access to the bile duct can be 
assured in subsequent exchange maneuvers. The cutting wire is then bowed 
so that it is in contact with the roof of the papilla. The incision is made in a 
stepwise manner in the 11–1 o’clock direction along the longitudinal fold.               
To avoid an uncontrolled ‘zipper’ cut, minimal tension is applied to the wire. 
 The electrocautery unit should be set with a high cutting current blended 
with a low coagulation current.  
                     The size of the sphincterotomy can vary but it should be limited 
to the junction between the duodenal wall and the intraduodenal portion of 
the ampulla of Vater, which often appears as a semicircular mucosal fold 
above the papilla. 
Rendezvous procedure (two-hands technique) 
                    A guidewire is passed through the percutaneous catheter down 
to the common duct and duodenum, which is to be picked up by a snare 
inserted through a duodenoscope. The guidewire is pulled out from the 
biopsy valve of the duodenoscope and a wire-guided sphincterotome is 
threaded over the guidewire into the common duct.  
                    Subsequent endoscopic sphincterotomy and stone extraction can 
be performed in the standard manner. In a series reported by Calvo et al., the 
success rate for clearing the CBD with a rendezvous approach was 93% 
(13/14) [87]. Only one complication was encountered, retroperitoneal 
perforation during sphincterotomy. This approach is an extremely good 
option for patients with poor surgical risks and refractory 
choledocholithiasis. 
                     We used rendezvous technique in one patient, in whom 
cholecystectomy state with T tube in situ.  
 
Stone extraction 
                    After endoscopic sphincterotomy, stones in the biliary tree can 
be removed with either a basket or a balloon catheter. We generally prefer a 
retrieval balloons than  dormia basket. 
Basket stone extraction  
                    In brief, the closed basket covered by its plastic sheath 
is inserted into the common duct through the therapeutic channel of the 
duodenoscope. Inside the bile duct, the basket is gently opened and contrast 
is injected to confirm its position and relation to the biliary calculi.  
                    Care must be taken when opening the basket because stones in 
the main duct may be displaced upward and become trapped in one of the 
intrahepatic ducts. It is also advisable to remove stones lying in the distal 
CBD before making any attempts to retrieve stones located in the proximal 
duct. Vigorous shaking of the fully open basket inside the bile duct may help 
to bring the stones into the basket. 
                     Once the stones are captured, the basket is withdrawn slowly 
without closure. Closure of the basket at this juncture may disengage the 
 stones. When the basket and stones are withdrawn to the level of 
papillotomy, the duodenoscope is gently pushed in with a right rotational 
movement. This maneuver helps straighten the tip of the duodenoscope, and 
exerts a traction force along the axis of the CBD which facilitates the 
removal of the stones, and avoids damage to the papilla or duodenum. By 
repeating the above maneuver, multiple ductal stones < 1 cm in diameter can 
be removed in the same ERCP session 
Balloon stone extraction  
                     Biliary stones in the CBD of < 1 cm in diameter can be 
removed with a balloon catheter. The balloon is deflated and inserted into 
the CBD through the sphincterotomy, and advanced above the stones. The 
balloon is gently inflated to the size of the bile duct and pulled back gently, 
displacing the CBD stone distally.  
                     With an adequate sphincterotomy, the stone can be pulled 
against the cut orifice and then expelled by traction on the balloon catheter 
followed by downward angulation of the tip of the endoscope. The 




 The challenge: giant CBD stones 
                     The ordinary endoscopic methods described above are suitable 
for stones around 1 cm in size. For stones > 1.5 cm in diameter, endoscopic 
retrieval becomes difficult, if not impossible. Several options are available to 
tackle the situation. They are basket mechanical lithotripsy, electrohydraulic 
lithotripsy, intraductal laser lithotripsy, stenting and interval endoscopic 
lithotripsy, and  Extracorporeal shock-wave lithotripsy (ESWL). 
Effects of stenting on CBD stones 
                     The exact mechanism causing the change in the size of stones 
is unclear, but improvement in the solubility of bile after drainage as well as 
the mechanical friction between stents and calculi are thought to be 
responsible. 
 The need for stone extraction after stenting  
                     Temporary drainage and decompression of the biliary system 
by a plastic stent are a valid option for high surgical risk patients whose 
stones are too big for endoscopic retrieval at the outset. 
                     However, in a prospective randomized trial by Chopra et al., 
significantly more long-term biliary complications were observed in patients 
treated with endoprosthesis as compared to those with complete ductal 
clearance [88]. Thus it is highly advisable to clear all common duct calculi 
 and reserve stenting as a definitive treatment only for those who are 
extremely unfit for other procedures. 
                          All patients with CBD stones underwent biliary sphinterotomy, 
along with either balloon trolleying or basketing and stenting. All patients’ 
clinical features, success rate and complications of endotherapy were 
documented. 
                    We used  PENTAX Video Duodenoscope of length 156 cms,  
working channel diameter of 4.2mm, field of view 110 degrees [ Model No:  
ED 341 C Batch No: A120052] with a   PENTAX Video Processor EPK  
150C input 100-240 V – 50/60 HZ ranging 300VA Max.   
                    We used ERBE ENDOCUT [Model ICC 200 EA INT ] for 
biliary sphincterotomy with cutting current 120 effect 3 without coagulation.   
                     We used  ERCP cannulas -  Fluro tip [Triple Lumen with 
Curved Tip], Guide wires Zebra 0.035” 450 cms [Bavarian wire, Medi –
Globe], X –Wire [ConMed ] ,Biliary Stone  Extraction Balloon – Inflated 
balloon size 14 – 16 mm [Medi –Globe], Wilson-Cook Triple Lumen Bow  
Sphincterotome, Triple Lumen Needle Knife Sphincterotome,[ Wilson-Cook 
Cutting wire 4mm ],  Sohendra Biliary Dilatation  Catheters [7 Fr, 10 Fr ], 
Web  Extraction Basket 2cms × 4 cms  [Cook Medical ], OASIS 10 Fr [One 
 Action Stent Introduction System ], Stent Pusher 7 Fr, Biliary stents 7 Fr, 10 
Fr  [Double Pigtail, Amsterdam ] of varying lengths.  
                    Cholangiogram was done by using IOHEXOL USP equiv. to 
350 mg of Iodine [Omnipaque ] . 
                    Patients with CBD stones are divided into three groups. 
Group 1- Patients with CBD stones with GB stones. 
Group 2- Patients with CBD stones with no stones in GB. 
Group 3- Patients with CBD stones in postcholecystectomy state. 
STATISTICAL METHODS: 
                     The statistical software package SPSS for Windows version 15 
[SPSS Inc, Chicago, III] was used to analyse the data. Means and Standard 
deviations were used to summarize data for continuous variables whereas 
percentages were used for categorical variables.  
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                     In this study, the patients were divided into three groups. 
       Group 1- Patients with CBD stones with GB stones. 
      Group 2- Patients with CBD stones with no stones in GB. 
                 Group 3- Patients with CBD stones in postcholecystectomy state 
                     Total number of patients underwent ERCP in our study were 
115. Out of which 51 were males and 64 were females. Overall success rate 
was 91.3%. Failure rate was 8.69%. The procedure was successful in 95 
patients in first attempt, 12 patients in second attempt, and 8 patients in third 
attempt. 
                    Abdominal pain was the presenting symptom in 70 [60.86%] 
patients, Jaundice in 44 [38.26%], Fever in 42 [36.52%], Charcots triad in 38 
[33.04%], Biliary pancreatitis in 6 [5.21%], Asymptomatic in 4 [3.47%] 
patients. 
                     38 patients developed post procedural abdominal discomfort, 
13 patients developed pancreatitis [Mild-9, Moderate -4, and Severe - 0], 
and 2 patients had retroduodenal perforation. No post sphincterotomy 
bleeding noted. No procedure related mortality was noted in this study. 
                      Biliary ascariasis was seen in one patient, choledochal cyst type 
1 was seen in 2 patients, periampullary diverticulum was seen in 15 patients, 
distal CBD stricture was seen in 19 patients. 
 Group 1- Patients with CBD stones with GB stones 
                      Total number of patients in this group were 62 ( male 29, 
female 33). Mean age of 51.16 yrs. Success rate in this group was 90.32% 
(56/62). Failure rate was 9.67% (6/62). The procedure was successful in 1st 
attempt in 54 pts, 2nd attempt in 5 pts, and 3rd attempt in 5 pts.  
                       Pain was the  predominant presenting symptom in 64.5%, 
followed by jaundice in 32.25%, and fever in 27.41%. Charcot’s triad was 
seen in 29.03%. Biliary pancreatitis was seen in 4.83%. Patients remain 
asymptomatic in 3.22%. 
                       Post procedural abdominal discomfort was noted in 20 
patients. Mild pancreatitis in 5 pts, moderate pancreatitis in 2 pts, perforation 
in one patient, and cholangitis in 3 patients were observed. 
                      Distal CBD stricture was seen in 10 pts, periampullary 
diverticulum was seen in 9 pts, choledochal cyst type 1 was seen in one 
patient, and intra hepatic stones was seen in 2 patients.  
 
 
 Group 2- Patients with CBD stones with no stones in GB 
                      Total number of patients in this group were 25 ( male 12, 
female 13). Mean age of 50.05 yrs. Success rate in this group was 88% 
(22/25). Failure rate was 12% (3/25). The procedure was successful in 1st 
attempt in 18 pts, 2nd attempt in 2 pts, and 3rd attempt in 3 pts.  
                       Pain was the  predominant presenting symptom in 48%, 
followed by fever in 52%. and jaundice in 44%,  Charcot’s triad was seen in 
44%. Biliary pancreatitis was seen in 4%. Patients remain asymptomatic in 
8%. 
                       Post procedural abdominal discomfort was noted in 8 patients. 
Mild pancreatitis in 2 pts, moderate pancreatitis in one patient, perforation in 
one patient, and cholangitis in one patient were observed. No undue bleeding 
or procedure related mortality were observed. 
                      Distal CBD stricture was seen in 5 pts, periampullary 
diverticulum was seen in 4 pts, biliary ascariasis was seen in one patient, 
choledochal cyst type 1 was seen in one patient, and intra hepatic stones was 
seen in 2 patients.  
Group 3- Patients with CBD stones in postcholecystectomy state 
                      Total number of patients in this group were 28 ( male 10, 
female 18). Mean age of 48.7 yrs. Duration after cholecystectomy  < 4 
 weeks in  3 pts, 4 weeks to 6 months in 4 pts, 6 months to 1 year in 6 pts, 1yr 
to 3yrs in 7 pts, 3yrs to 5yrs in 5 pts, 5yrs to 10yrs in 2 pts, and > 10yrs in 1 
patient. Success rate in this group was 96.4% (27/28). Failure rate was 
3.57% (1/28). The procedure was successful in 1st attempt in 23 pts, and 2nd 
attempt in 5 pts.  
                       Pain was the predominant presenting symptom in 64.28%, 
followed by jaundice in 50%, and fever in 42.85%. Charcot’s triad was seen 
in 32.14%. Biliary pancreatitis was seen in 7.14%. No patients remain 
asymptomatic in this group. 
                       Post procedural abdominal discomfort was noted in 10 
patients. Mild pancreatitis in 2 pts, moderate pancreatitis in one patient,  and 
cholangitis in one patient were observed. No undue bleeding or procedure 
related mortality were observed. 
                      Distal CBD stricture was seen in 4 pts, and periampullary 






 DEMOGRAPHIC PROFILE 
 
S.N  TOTAL GROUP-1 GROUP-2 GROUP-3 P 
value 
1 Number 115 62 25 28  
2 Male:Female 51:64 29:33 12:13 10:18 0.568 











4. Success rate 105/115=91.3 56/62=90.32% 22/25=88% 27/28=96.4% 0.51 









6. Number of 
attempts 
1st – 95 
2nd – 12  
3rd – 8   
1st – 54 
2nd – 5 
3rd – 5  
1st – 18 
2nd – 2 
3rd – 3 
1st – 23 
2nd – 5  
3rd – 0   
0.104 
 





















































 CLINICAL PRESENTATIONS 
 
S.NO. Features Total Group – 1  Group-2 Group – 3 P 
value 
1. Pain 70/115=60.86% 40/62=64.5% 12/25=48% 18/28=64.28% 0.329 
2. Jaundice 44/115=38.26% 20/62=32.25% 11/25=44% 14/28=50% 0.238 
3. Fever 42/115=36.52% 17/62=27.41% 13/25=52% 12/28=42.85% 0.071 
4. Charcots triad 38/115=33.04% 18/62=29.03% 11/25=44% 9/28=32.14% 0.403 
5. Pancreatitis 6/115=5.21% 3/62=4.83% 1/25=4% 2/28=7.14% 0.859 
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38/115=33.04% 20/62=32.25% 8/25=32% 10/28=35.7% 0.942 
2. Pancreatitis- 
Mild 
9/115=7.82% 5/62=8.06% 2/25=8% 2/28=7.14% 0.988 
 Moderate 4/115=3.47% 2/62=3.22% 1/25=4% 1/28=3.57% 0.984 
3. Perforation 2/115=1.73% 1/62=1.61% 1/25=4% 0 0.535 
4. Cholangitis 5/115=4.34% 3/62=4.83% 1/25=4% 1/28=3.57% 0.412 
5. Sphincterotomy 
bleeding 
0 0  0  











 ASSOCIATED FEATURES 
 
S.NO. Features Total Group – 1  Group-2 Group – 3 P 
value 
1. Distal CBD 
stricture 
19/115=16.52% 10/62=16.12% 5/25=20% 4/28=14.28% 0.849 
2. Periampullary 
diverticulum 
15/115=13.04% 9/62=14.52% 4/25=16% 2/28=7.14% 0.557 
3. Biliary 
ascariasis 
1/115=0.87% 0 1/25=4% 0 0.163 
4. Choldochal 
cyst 
2/115=1.74% 1/62=1.61% 1/25=4% 0 0.535 
5. Intra Hepatic  
Stones 




























                                                                                                                    
  
                     In this study, the patients were divided into three groups. 
       Group 1- Patients with CBD stones with GB stones. 
      Group 2- Patients with CBD stones with no stones in GB. 
      Group 3- Patients with CBD stones in postcholecystectomy state. 
 
                    Various clinical presentations, success rates, complications                           
of endotherapy and associated features in these groups were studied. 
                     Similarly patients with CBD stones were divided into three 
groups by Kumar et al, AIIMS New Delhi [64]. They studied clinical and 
biochemical features of different types of CBD stones. 
                     Rakesh K Tandon et al [65] divided patients with CBD stones 
intotwo groups and studied prevalance and type of biliary stones in India. 
                     In this study 62 patients [71.26%] had GB stones. In Kumar et 
al’s study, 42 patients [56.7%] had GB stones. In my study, 25 patients had 
isolated CBD stones. Out of these 25 patients five had distal CBD stricture, 
one had biliary ascariasis, one had type 1 choledochal cyst and two had intra 
hepatic stones & recurrent pyogenic cholangitis. Others could not have any 
identifiable risk factors for CBD stones. 
  
                    In this  study overall success rate was 91.3% and failure rate 
was 8.69%. The procedure was successful in 95 patients in first attempt, 12 
patients in second attempt, and 8 patients in third attempt. Other studies did 
not mention the number of attempts for CBD cannulation. Success rate and 
failure rate were similar in all three groups (P value 0.510).   
                     CBD could not be cannulated in ten patients. Out of these ten, 
three had total gastric outlet obstruction, three had Post GJ status with 
surgically altered anatomy [Billroth II], two had partial gastric outlet 
obstruction with difficulty in maintaining the scope position and another two 
had anomalous position of ampulla. 
                     Overall complication rate was 13.04%. Post ERCP pancreatitis   
occurred in 13 patients [11.30%]. 5 male, 8 female patients. Out of these, 9 
[7.82%] had mild and 4 [3.47%] had moderate pancreatitis. Silvano 
Loperfido et al observed moderate to severe pancreatitis in 1.3% [68]. Martin 
L Freeman observed pancreatitis in 6.73% of patients. 
 
                    Mild pancreatitis is defined as clinical pancreatitis, s.amylase 
atleast three times normal or more at 24 hrs after the procedure and 
prolongation of planned admission to 2 – 3 days.[67] Moderate pancreatitis 
requiring hospitalization of 4 – 10 days. Severe pancreatitis requiring 
 hospitalization of more than 10 days, or pseudocyst or require intervention 
[21]. 
                    In two large prospective studies pancreatitis rates ranged 
between 0.74% for diagnostic  and 1.4% for therapeutic ERCP  in one study 
[36 ]
 compared with 5.1% [ 7 times higher] for diagnostic ERCP and 6.9% [ 5 
times higher]  for therapeutic ERCP in another prospective study [28 ].  
Pancreatitis rate in all the 3 groups were same (P value 0.984). 
                     Two patients [1.73%] in my study had perforation after ERCP 
similar to Freeman et al study [66]. Both of them were treated conservatively 
and they recovered. P value (0.535) not significant in these groups.  
                     In the study, 5 pts (4.34%) had post ERCP cholangitis. 3 pts in 
group 1, one patients each in group2 & 3. P value (0.412) not significant. 
Risk factors for cholangitis after ERCP and sphincterotomy consist primarily 
of failed or incomplete biliary drainage [70]. All the patients treated with IV 
antibiotics and they recovered very well. 
                     None of the patients in the study group had post 
sphincterotomy bleeding and no mortality was observed. Post 
sphincterotomy bleeding was observed 0.5 – 2 % of patients in Freeman et al 
study [66]. 
                      In this study, CBD stones were slightly more common in 
females (F 64 pts, M 51 pts). Mean age of presentation was 49.91 years 
(range 9 – 76 yrs). A. J. Sheen observed Male-to-female ratio was 1: 3 with 
a median age of 54 years (range: 17–93). [69].  
                    Most common presentation of CBD stones in my study was 
abdominal pain 60.86%, followed by jaundice 38.26%, and fever 36.52%.. 
Charcots triad was seen in 33.04% .Biliary pancreatitis was seen in 5.21%. 
patients remain asymptomatic in 3.47%. A J Sheen et al observed jaundice 
in 7.1%, pancreatitis in 6.3%, Cholangitis in 6.8%.[69] There was no 
significant difference in the clinical presentations in all the 3 groups (P value 
> 0.238). 
                  In this study biliary ascariasis was seen in one patient, 
choledochal cyst type 1 seen in 2 patients, periampullary diverticulum seen 
in 15 patients, distal CBD stricture seen in 19 patients, Intra hepatic stones in 
3 patients. Patients with CBD strictures dilated with 7 Fr, 10Fr Sohendra 
biliary dilatation catheters. 
                     In the study biliary stenting was done in 80 patients. All 
patients with      GB stones, distal CBD stricture, intrahepatic stones and 
multiple large stones were stented with 7 Fr, 10 Fr [Double Pigtail, 
 Amsterdam] of varying lengths. ESWL was not used because of 
unavailability of the facility. 
                     Limitations of this study were  
1. CBD stone analysis was not done  
2.Not using ESWL and not giving duct clearance in all the patients. 



























1. Most common presentation of CBD stones in this study was abdominal 
pain 60.86%, followed by jaundice 38.26%, and fever 36.52%.Charcots triad 
was seen in 33.04%.   
2. In the study, overall success rate was 91.3% and failure rate was 8.69%. 
 3. Overall complication rate was 13.04%. No post sphincterotomy bleeding 
was noted. No procedure related mortality was noted. Hence endotherapy 
are very effective with fewer complications in the treatment of 
choledocholithiasis. 
  4.  CBD Stones were more common in females (F- 64 pts, M- 51 pts). 
Mean age of presentation was 49.91 years (range 9 – 76 yrs). 
  5.  Biliary ascariasis was seen in one patient, choledochal cyst type 1 was 
seen in 2 patients, periampullary diverticulum was seen in 15 patients, distal 
CBD stricture was seen in 19 patients and intra hepatic stones were seen in 3 
patients. 
  6. There was no statistically significant difference in clinical presentations, 
associated features, success rate and complications of endotherapy in   
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S.NO NAME AGE/SEX DDHDNO 
ERCP 
NO PRESENTATION GROUPS ENDOTHERAPY COMPLICATIONS OTHERS 
 1 Ranganathan 71/M 1146/08 34/08  Charcots triad 2 BA,ST ABD.DISCOMFORT Divert 
2 Bhakila 29/F 1120/08 40/08 Fever  1 BA,ST ABD.DISCOMFORT  
3 Indirani 50/F 2311/08 46/08 pain Fever 1 BA CHOLANGITIS  
4 Kullammal 60/F 2405/08 47/08 pain Fever 1 BA,ST MILD PANCREATI  
5 Natarajan 50/M 2625/08 53/08  Charcots triad 2 BA,Bask,St   
6 Manohar 45/m 2643/08 54/08 Jaundice  1 Failed  3A 
7 Rajeshwari 45/F 5675/06 59/08 Charcots triad 3 D,BA,Bask,St ABD.DISCOMFORT Stricture 
8 Karnan 38/M 2685/08 60/08 pain Fever 2 BA,ST   
9 Adhilakshmi 40/F 2741/08 61/08 Jaundice  3 BA,st CHOLANGITIS  
10 Vijaya 38/F 2854/08 63/o8 Charcots triad 3 Ba MILD PANCREAT  
11 Baby 50/F 2876/08 70/08 Jaundice  1 BA,Bask,St,D  stricture 
12 Ganga 70/F 2797/08 71/08 Jaundice  1 St ABD.DISCOMFORT Divert,pa.gr 
13 Saravanan 32/M 2758/08 72/08  Charcots triad 2 St ABD.DISCOMFORT  
14 Rackeljoseph 60/F 2757/08 74/08 pain Fever 3 REN,Ba,Bask,   
15 Rosemary 43/F 2978/08 76/08  Charcots triad 2 BA,Bask,St,D  2A,Stricture 
16 Rajan 58/M 2917/08 77/08 pain Fever 1 BA,ST CHOLANGITIS  
17 Suseela 65/F 2891/08 81/08 pain Fever 1 St   
18 Gopunaidu 63/M 500/03 83/08  Charcots triad 3 BA,Bask,St,D MILD PANCREAT stricture 
19 Bama 35/F 3076/08 86/08  Charcots triad 1 BA,ST,D ABD.DISCOMFORT 3A, Stricture 
20 Karunakaran 58/M 3253/08 89/08 pain Fever 2 BA,ST   
21 Rukmani 58/f 3365/08 94/08  Charcots triad 1 Ba,Bask,St   
22 Baskar 59/M 3393/08 95/08  Charcots triad 2 BA,Bask,St ABD.DISCOMFORT  
23 Chitra 26/F 2114/08 98/08 pain Fever 1 BA,ST   
24 Prasanna 30/F 3527/08 100/08  Fever 1 BA,Bask,St,D ABD.DISCOMFORT 
Stricture, 
ASCARI 
25 Narayanan 72/M 2594/07 103/08  Charcots triad 1 BA,Bask,St,D ABD.DISCOMFORT 3A,stricture 
26 Kamala 75/F 3744/08 104/08 Jaundice  2 BA,ST,D  2A,stricture 
27 Rudhmary 35/F 3855/08 107/08 pain Fever 1 BA,ST MODERATE PAN  
28 Vasantha 48/F 4044/08 111/08 pancretitis 1 BA,ST   
29 Malaiammal 45/F 4046/08 113/08  Charcots triad 3 BA,ST MODERATE PAN 2A 
30 Thayarammal 70/F 4445/08 118/08 Charcots triad 3 BA,Bask,St  DIVERTICULUM 
31 Vasu 47/M 2709/08 120/08 Jaundice  2 Failed  2A, Divert,GOO 
32 Alagammal 53/F 5404/07 126/08 Jaundice Fever 1 BA,ST ABD.DISCOMFORT Ch.cyst1a 
33 Sengani 70/M 4500/08 127/08 pancreatitis 1 BA,ST ABD.DISCOMFORT  
34 Amsa 51/F 4591/08 129/08 pain Fever 2 BA,Bask,St   
35 Kathiresan 62/M 3885/06 134/08 pain 3 BA,ST ABD.DISCOMFORT  
36 Sakunthala 31/F 4596/07 135/08 Charcots triad 1 BA,Bask,St   
37 Eswari 43/F 5081/08 136/08  Charcots triad 3 Ba,ST,D ABD.DISCOMFORT Stricture 
38 Akilandam 75/F 5128/08 140/08  Charcots triad 1 BA,Bask,St   
39 Abdulrahman 65/M 5244/08 141/08 Charcots triad 2 Ba,st MILD PANCREATI  
40 
Murugan 
chettiyar 76/M 1040/01 143/08 Jaundice  1 BA,Bask,St   
41 Brindhakumari 50/F 5346/08 142/08 Jaundice Fever 2 Ba  
Intrahepatic 
stones 
42 Ameenabee 65/F 4670/08 149/08 asymptomatic 1 Ba, ABD.DISCOMFORT Divert 
43 Mamtha 70/F 5381/08 152/08 Jaundice  1 BA,ST  Divert, 
 44 Sankari 70/F 4500/08 153/08 Charcots triad 3 Ba ABD.DISCOMFORT  
45 Sakila 29/F 1878/08 158/08 pain Fever 3 Ba   
46 Lakshmi 35/F 5889/08 164/08 pain Fever 1 Failed  Partial GOO 
47 subramaniyan 54/M 6014/08 167/08 Jaundice  2 BA,Bas,St,D ABD.DISCOMFORT Stricture 
48 Bharathi 55/F 6069/08 169/08 pain 1 D,BA,ST  G,Stricture 
49 Kalimuthu 50/M 6615/08 004/09  Charcots triad 3 BA,st  3A,Divert 
50 Ranganayaki 76/F 207/09 008/09 pain 1 Failed ABD.DISCOMFORT 3A, Post GJ 
51 Asanbanu 35/F 3036/06 012/09 Jaundice Fever 1 BA,st,D MODERATE PAN stricture 
52 Sathyapriya 28/F 354/09 014/09 Jaundice  1 BA, ST  3A 
53 Pushpa 65/F 361/09 015/09 Jaundice Fever 1 Ba,st  Divert 
54 Kanthasamy 70/M 399/09 018/09  Charcots triad 2 Ba,st,D MILD PANCREAT 3A,stricture 
55 Arumugam 58/M 4695/00 022/09 Jaundice  3 BA,st ABD.DISCOMFORT  
56 Arivalagan 35/M 463/09 025/09 Jaundice Fever 1 BA,st,D ABD.DISCOMFORT stricture 
57 Chellapan 45/M 599/09 029/09 pain Fever 1 Ba,st PERFORATION 3A,ch.pan 
58 Duraisamy 74/M 595/09 030/09 asymptomatic 1 Ba,st ABD.DISCOMFORT  
59 Saraswathi 33/F 725/09 036/09 pancreatitis 2 BA,st,D  stricture 
60 Kanthasamy 60/M 595/09 043/09 pain Fever 1 Failed  Fistula 
61 Hasina 38/F 870/09 044/09 Charcots triad 3 BA,st ABD.DISCOMFORT 2A 
62 Bhoopathi 70/M 886/09 046/09 pain 1 Ba,st,D  ,Stricture 
63 Kansiabegum 65/F 897/09 048/09  Charcots triad 2 BA,st MODERATE PANC  
64 Durai 65/M 1129/09 051/09 pain 1 Ba,st   
65 Mohana 38/F 1151/09 055/09 Jaundice Fever 3 D,BA,ST,D ABD.DISCOMFORT 2A, Stricture 
66 Balammal 55/F 1463/09 057/09 pain 1 Ba,st   
67 Jeyarani 58/F 1985/09 064/09 Charcots triad 2 Failed  Post GJ 
68 Ameenabee 65/F 4620/08 065/09 Jaundice  1 St MILD PANCREATI Divert 
69 Dhanalakshmi 45/F 2337/09 072/09 pain 1 BA,st   
70 Arthi 30/F 2543/09 075/09 pain Fever 1 Ba,st ABD.DISCOMFORT 
71 Muthusamy 62/M 6383/02 076/09 Charcots triad 1 Ba,St  2A 
72 Jayalakshmi 46/F 2619/09 079/09 asymptomatic 2 BA,st ABD.DISCOMFORT Divert 
73 Narayanan 43/M 2685/09 082/09 pancreatitis 1 Ba,st   
74 Srisha 24/F 2781/09 084/09 pain Fever 1 Ba,st,D  stricture 
75 pakkirisamy 48/M 1482/09 087/09  Charcots triad 2 Ba,st PERFORATION  
76 Thilagavathi 55/F 2758/09 088/09 pain 1 Ba,st   
77 Balammal 65/F 2468/09 95/09 Charcots triad 3 Ba.st ABD.DISCOMFORT  
78 Rajeshwari 65/F 3532/09 100/09 pain Fever 1 Ba,st  2A,Needle 
79 Umamaheswari 41/F 5834/01 107/09 pain Fever 3 Ba   
80 Harikrishnan 24/M 3681/09 108/09  Charcots triad 1 Ba,st ABD.DISCOMFORT  
81 Rathinavel 44/M 4058/09 121/09 pain 3 Ba   
82 Valliammal 65/F 4886/09 123/09 pain 1 Ba,st   
83 Mariammal 50/F 411/09 124/09  Charcots triad 1 BA,st ABD.DISCOMFORT Needle, 
84 vijayakumar 31/M 406/09 126/09 pain Fever 1 Ba,st MILD PANCRETI 2A,Needle 
85 Lakshmi 70/F 4462/09 136/09  Charcots triad 2 Ba,st   
86 Rani 35/F 4482/09 137/09 pain 1 D,BA,ST ABD.DISCOMFORT  
   
 Group 1- Patients with CBD stones with GB stones. 
      Group 2- Patients with CBD stones with no stones in GB. 
                 Group 3- Patients with CBD stones in postcholecystectomy state  
                 Ba – Balloon trolleying 
                 Bask – Basketing  
                 St – Biliary stenting 
                 D -  Bliary dilatation  
87 Selvakumar 45/M 4540/09 139/09 pain Fever 2 Failed ABD.DISCOMFORT 
Divert, Partial 
GOO 
88 Sridhar 40/M 4667/09 140/09  Charcots triad 3 D,BA,ST   
89 Alagammal 70/F 3527/09 145/09 pain 1 BA,st MILD PANCREATI  
90 Ameen 66/M 4782/09 149/09 Jaundice  1 BA,st ABD.DISCOMFORT 
In.Hepatic 
stones 
91 Mahalakshmi 52/F 4854/09 150/09 pain 1 BA,st   
92 Karuna 34/M 4803/09 152/09 pain Fever 2 Failed ABD.DISCOMFORT  Divert 
93 Sundarrajan 48/M 4823/09 157/09 pain 1 BA,st   
94 Sivagangaram 48/M 4836/09 158/09 pain Fever 1 Ba,st,D ABD.DISCOMFORT stricture 
95 Alagan 46/M 4917/09 159/09  Charcots triad 1 BA,st ABD.DISCOMFORT Needle 
96 Jaimulabdeen 39/M 5142/09 164/09 pain 1 Ba,st   
97 Jaleel 35/M 5173/09 165/09 pain Fever 3 Ba ABD.DISCOMFORT  
98 Kamalakannan 41/M 5255/09 168/09 pain 1 Ba,St   
99 Kathiresan 38/M 5489/09 172/09  Charcots triad 1 BA,st MILD PANCREATI 2A,fistula 
100 Balakrishnan 60/M 5573/09 173/09 pain 1 Ba.st MILD PANCREATI  
101 Sanjeevi 53/M 5632/09 175/09  Charcots triad 1 BA,st ABD.DISCOMFORT Needle,fistula 
102 Gayathridevi 56/F 5557/09 176/09 pain Fever 1 BA,ST  2A 
103 Madhan 48/M 5750/09 183/09  asymptomatic 2 BA,st ABD.DISCOMFORT Divert 
104 Vinothini 9/F 5718/09 185/09 pain 1 BA,st  Ch.CYST 
105 Jegan 24/M 5898/09 192/09  Charcots triad 1 BA,st   
106 Kumaravadivel 50/M 6079/09 197/09 Jaundice  3 Ba,st   
107 Pitchumani 68/M 6115/09 199/09 Charcots triad 1 Failed  DU,GOO 
108 Anitha 45/F 6171/07 203/09 Jaundice  2 Ba,st,D CHOLANGITIS Stricture 
109 Gunasekar 37/M 6162/09 204/09 pain 1 Failed ABD.DISCOMFORT 2A 
110 Alamelu 65/F 6185/09 205/09 Jaundice Fever 2 Ba,st   
111 Sridhar 40/M 4667/09 206/09 pain 3 Failed   
112 Dhanalakshmi 50/F 6324/09 217/09 Pancreatitis 3 Ba,st ABD.DISCOMFORT  
113 Mahalakshmi 39/F 4761/09 219/09 Pancreatitis 3 Ba,st   
114 Rani 47/F 3354/09 226/09  Charcots triad 2 St,D  Stricture 
115 Sengaiyan 75/M 6425/09 228/09 pain Fever 1 Ba,st CHOLANGITIS  
          
                  Divert – Periampullary diverticulum 
                 2A – 2nd attempt 
                 3A – 3rd attempt 
                 GOO- Gastric Outlet Obstruction 
 
 
